Bilimsel Program
Üç gün boyunca on dört oturum — her biri bir açılış tartışmasıyla başlayıp tartışmayla kapanıyor — uydu sempozyumları ve sözlü bildiri sunumlarıyla birlikte.
1. Gün — 30 Mart 2027
Bu günün oturumları Türkçe yapılacaktır.
-
13:00-14:30
-
14:30-15:15
- 15:15-15:30 Kahve molası
-
15:30-17:00
-
17:00-17:45
- 17:45-18:00 Kahve molası
-
18:00-19:00
-
19:00-20:00
-
20:00-20:15
2. Gün — 31 Mart 2027
-
09:00-10:30
Official Opening & Presentation of the Istanbul MS Days Award
-
09:00-09:20
Opening Ceremony
- 5-minute inspirational video “Patients’ Voice: What do our patients expect from us?”
- Short comments by chairs
-
09:20-09:35
Welcome address 1
Tree of Life: The interconnected roots of existence
-
09:35-09:50
Welcome address 2
From roots to fruits in MS & Autoimmunity
-
09:50-10:00
Presentation of the Istanbul MS Days 2027 Award
-
10:00-10:30
Istanbul MS Days Lecture başlık daha sonra duyurulacak
-
09:00-09:20
- 10:30-10:45 Ara
-
10:45-12:20Session 1
Seeds of MS
-
10:45-11:00
Açılış tartışması
Is inheritance of MS genetic or epigenetic?
Genetic vs Epigenetic
Konuşmacı başına 6 dakika, elektronik oylamayla
-
11:00-11:20
Genetic risk of MS is underestimated
-
11:20-11:40
Epigenetic inheritance of MS shapes diversity in MS outcomes
-
11:40-12:00
Is EBV the only trigger of MS or tip of the iceberg?
-
12:00-12:20
Q&A and discussion
-
10:45-11:00
-
12:20-13:45
-
13:45-15:20Session 2
Seeds to Initial Roots of MS
-
13:45-14:00
Açılış tartışması
Does the immune system have a master regulatory cell?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
14:00-14:20
Tregs matter in MS
-
14:20-14:40
Bregs matter more than Tregs in MS
-
14:40-15:00
Role of monocyte lineage in immunoregulation in MS
-
15:00-15:20
Q&A and discussion
-
13:45-14:00
- 15:20-15:35 Ara
-
15:35-17:10Session 3
Establishing the Root System in MS
-
15:35-15:50
Açılış tartışması
Does the CNS have a master regulatory cell?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
15:50-16:10
The unbearable heaviness of being an astrocyte
-
16:10-16:30
Oligodendrocytes: Between a rock and a hard place
-
16:30-16:50
Microglia: Master of cells or Orion?
-
16:50-17:10
Q&A and discussion
-
15:35-15:50
- 17:10-17:25 Ara
-
17:25-19:00Session 4
Connecting the Root System in MS
-
17:25-17:40
Açılış tartışması
AI will reshape our understanding of MS & autoimmunity
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
17:40-18:00
How to build AI into the future of medical education
-
18:00-18:20
Using AI to solve the unsolvable: Examples from the real world
-
18:20-18:40
Using the roots rather than the fruits of disease to redefine the phenotypes of MS: An AI-based approach
-
18:40-19:00
Q&A and discussion
-
17:25-17:40
-
19:00-19:30
3. Gün — 1 Nisan 2027
-
08:00-08:50
-
09:00-10:35Session 5
Clinical Branches of MS
-
09:00-09:15
Açılış tartışması
Does MS have distinct phases?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
09:15-09:35
All relapses are equal, but some relapses are more equal than others
-
09:35-09:55
The biology of progressive MS is a continuum that starts from the beginning
-
09:55-10:15
The makeup of cumulative disability in MS: Why do we see “benign” and severe extremes?
-
10:15-10:35
Q&A and discussion
-
09:00-09:15
- 10:35-10:50 Ara
-
10:50-12:25Session 6
Imaging Branches and Fruits of MS
-
10:50-11:05
Açılış tartışması
Molecular imaging is as important as MRI for understanding the progressive MS phenotype
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
11:05-11:25
After the acute phase, some lesions continue to evolve: Smoldering and slowly expanding lesions in the CNS
-
11:25-11:45
MS is a diffuse slow burn within the CNS: The smoldering brain and atrophy at distant sites
-
11:45-12:05
Skull bone marrow in MS: Lessons from TSPO-PET
-
12:05-12:25
Q&A and discussion
-
10:50-11:05
-
12:25-13:50
-
13:50-15:35Session 7
Ripening the Fruits of MS
-
13:50-14:05
Açılış tartışması
Is it time to consider sex hormone-based therapy in MS?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
14:05-14:25
Mixing and matching sex chromosomes to dissect their impact on autoimmunity and MS
-
14:25-14:45
Too much or too little? How female hormones shape MS across the reproductive lifespan
-
14:45-15:05
How do male sex hormones impact MS?
-
15:05-15:35
Q&A and discussion
-
13:50-14:05
- 15:35-15:50 Ara
-
15:50-17:25Session 8
Harvesting better outcomes in MS starts with early diagnosis
-
15:50-16:05
Açılış tartışması
Will earlier diagnosis using the 2024 McDonald criteria meaningfully reduce long-term disability in MS?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
16:05-16:25
What are the clinical gold standards for validating MS diagnostic criteria?
-
16:25-16:45
Imaging gold standards for validating MS diagnostic criteria: Lessons from RIS and beyond, with potential implications for treatment outcomes
-
16:45-17:05
How should MS diagnostic criteria best be validated from a statistical perspective?
-
17:05-17:25
Q&A and discussion
-
15:50-16:05
- 17:25-17:40 Ara
-
17:40-19:15Session 9
Grafting the MS tree to bear a different fruit
-
17:40-17:55
Açılış tartışması
Can directly targeting microglia meaningfully improve outcomes in MS?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
17:55-18:15
CAR-T cell therapy in MS: What could it offer beyond current treatments, and at what risk?
-
18:15-18:35
Where are the promised remyelination therapies for MS?
-
18:35-18:55
Can endogenous neural stem and progenitor cells be mobilized for CNS repair in MS?
-
18:55-19:15
Q&A and discussion
-
17:40-17:55
-
19:15-19:45
- 19:45-20:00 Yemek öncesi ara
4. Gün — 2 Nisan 2027
-
08:00-08:45
-
09:00-10:35Session 10
Describing what to pick better in MS
-
09:00-09:15
Açılış tartışması
We already have pretty good clinical, biofluid and imaging biomarkers: Do we still need more biomarkers for MS?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
09:15-09:35
Unmet needs in imaging biomarkers for MS
-
09:35-09:55
Unmet needs in blood biomarkers for MS
-
09:55-10:15
Unmet needs in CSF biomarkers for MS
-
10:15-10:35
Q&A and discussion
-
09:00-09:15
- 10:35-10:50 Ara
-
10:50-12:25Session 11
Picking the hard-to-reach fruits in MS
-
10:50-11:05
Açılış tartışması
Cognitive and behavioral impairment is the most common and prominent disability in MS
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
11:05-11:25
Cognitive disability starts very early in MS
-
11:25-11:45
Radiomic features of cognitive impairment can be seen long before patients report symptoms
-
11:45-12:05
The hidden roots of cognitive impairment in MS: From cellular pathology to network failure
-
12:05-12:25
Q&A and discussion
-
10:50-11:05
-
12:25-13:50
-
13:50-15:25Session 12
Mimics of MS — From Roots to Fruits
-
13:50-14:05
Açılış tartışması
Can autoimmune mimics of MS be reliably distinguished from MS?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
14:05-14:25
Neurosarcoidosis: The orphaned mimic of CNS autoimmunity
-
14:25-14:45
Diagnosing without a gold standard: Do we need better criteria for Neuro-Behçet disease?
-
14:45-15:05
Other autoimmune mimics of MS, NMOSD and MOGAD
-
15:05-15:25
Q&A and discussion
-
13:50-14:05
- 15:25-15:40 Ara
-
15:40-17:15Session 13
From seeds to fruits in NMOSD
-
15:40-15:55
Açılış tartışması
Is AQP4-IgG-positive NMOSD our best model for precision therapy in CNS autoimmunity?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
15:55-16:15
What do longitudinal changes in AQP4-IgG and MOG-IgG really tell us about prognosis and treatment?
-
16:15-16:35
Beyond attack prevention in NMOSD: What remains unmet in treatment, recovery and long-term outcomes?
-
16:35-16:55
What lies behind double-seronegative NMOSD: A distinct disease entity or a heterogeneous group of disorders?
-
16:55-17:15
Q&A and discussion
-
15:40-15:55
- 17:15-17:30 Ara
-
17:30-19:05Session 14
From seeds to fruits in MOGAD
-
17:30-17:45
Açılış tartışması
Is MOGAD primarily a post-infectious autoimmune disease of the CNS?
Yes vs No
Konuşmacı başına 6 dakika, elektronik oylamayla
-
17:45-18:05
How common is MOGAD, really?
-
18:05-18:25
From antibodies and cellular mechanisms to clinical outcomes: The biology of MOGAD
-
18:25-18:45
The treatment saga in MOGAD: Whom to treat, when to start, what to use and for how long?
-
18:45-19:05
Q&A and discussion
-
17:30-17:45
-
19:05-19:35
-
19:35-19:50
- 19:50-20:15 Yemek öncesi ara
5. Gün — 3 Nisan 2027
Bu günün oturumları Türkçe yapılacaktır.
-
09:30-11:00
- 11:00-11:45 Ara
-
11:45-12:15
-
12:15-12:45
6 Eylül 2026 tarihli programdır. Oturum başkanları, tartışmacılar ve konuşmacılar ilerleyen günlerde duyurulacak; oturum başlıkları ve saatler değişebilir.